Patients Show Nearly Two-fold Clinical Improvement when Treatment Selection Informed by PrismRA; Predictive Blood Test Could Improve Efficiency in Health Care Spending
WALTHAM, Mass. (April 28, 2022) – Scipher Medicine, a precision immunology company matching each patient with their most effective therapy, today announced new data showing patients with rheumatoid arthritis (RA) whose treatment was informed by PrismRA had improved clinical outcomes and use of PrismRA could reduce health care spending. The data were published in Expert Opinion on Biological Therapy.
Data announced today come from the Study to Accelerate Information of Molecular Signatures (AIMS), which examined treatment and clinical outcomes for 470 patients whose health care providers used PrismRA, a blood test that analyzes RA patients’ molecular profiles to identify those unlikely to respond to tumor necrosis factor inhibitors (TNFi).
After six months, RA patients with moderate and high disease activity whose treatment was guided by PrismRA, showed a nearly two-fold clinical improvement in Clinical Disease Activity Index (CDAI) scores compared to patients whose therapy was not guided by PrismRA results. When a signature of non-response to TNFi was detected, more patients achieved low disease activity or remission when treated with a non-TNFi instead of a TNFi therapy (high disease activity 23% vs 17%; moderate disease activity 71% vs 47%). These data add to the growing evidence supporting the clinical utility of the PrismRA test to inform treatment selection for patients with RA.
“Effective early treatment can help improve the health-related quality of life for patients with rheumatoid arthritis,” said study co-author Vibeke Strand, M.D., adjunct clinical professor, Division of Immunology and Rheumatology, Stanford University School of Medicine. “Predictive tests, such as PrismRA, can eliminate the trial-and-error treatment selection approach in RA and result in better treatment outcomes.”
“These results further support PrismRA’s ability to significantly improve patient outcomes and demonstrate its potential to guide treatment decisions,” said Dr. Sam Asgarian, chief medical officer of Scipher Medicine. “Blood tests that reveal a person’s unique molecular disease signature and match it to the most effective existing therapy are clinically valuable and make a significant impact on patient treatment outcomes.”
PrismRA is a revolutionary blood test bringing precision medicine to the treatment of rheumatoid arthritis, which affects 20 million patients globally. From a routine blood draw, the PrismRA test analyzes an individual’s molecular signature, helping identify who is unlikely to adequately respond to TNFi therapy, the world’s largest selling drug class, so non-responders can be prescribed alternative effective therapy and avoid unnecessary dose escalations or drug cycles. Providers now have objective data to inform therapeutic decision-making and give patients the best chance of achieving treatment targets and improving clinical outcomes. For more information, please visit PrismRA.com.
About Scipher Medicine®
Scipher Medicine, a precision immunology company matching each patient with their most effective therapy, believes that patients deserve simple answers to treatment options based on scientific data. Using Spectra™, our proprietary network medicine platform, we commercialize tests revealing a person’s unique molecular disease signature and match it to the most effective therapy, ensuring optimal treatment from day one. The patient molecular data generated from our tests further supports the discovery and development of novel and more effective therapeutics. We partner with leading payers, pharmacy benefit managers, health care providers, and biotechnology pharmaceutical companies to bring solutions to patients with autoimmune diseases. Visit sciphermedicine.com and follow Scipher Medicine on Twitter, Facebook, and LinkedIn.
Director, Corporate Communications
VP, Head of Corporate Affairs